Medical Condition

unresectable bladder carcinoma

Total Trials

3

Recruiting Now

3

Trial Phases

Phase 2

ClinicalMetric tracks all active clinical trials for unresectable bladder carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Trial Phases

Phase 2

Top Sponsors

Dana-Farber Cancer Institute 1 trial

Emory University 1 trial

Roswell Park Cancer Institute 1 trial

NCT06138561

Recruiting

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Dana-Farber Cancer Institute

View Trial →

NCT05756569 Phase 2

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Roswell Park Cancer Institute

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology